Search This Blog

Sunday, June 3, 2018

110



This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.




Symfi-Lo... Finally!

By Charles-Edouard!
Another litany of abuse... ICCARRE quickly!
The mithridatization, that is to say the progressive habituation to poisons, inhibitoids or inhibitors, does not remove the toxicity. It is less perceived, that's all!

Symfi-Lo = TLE-400


Symfi-Lo is the first drug to market the TLE-400(Tenofovir-Lamivudine-Efavirenz 400 mg) mitigation strategy. We discussed it in our post WHO proves us right! Well... The progress of this case will have been extremely slow, and the practical implementation is coming on the market: it is not too early! Something must have tipped off some people, and the Kirby Institute has obtained funding($11 million, if memory serves) from the Bill and Melinda GATES Foundation to launch the ENCORE-1 trial.

This involves reducing the dose of Efavirenz from 600 mg to 400 mg

Mylan launches Symfi-lo in the US.

TLE-400 unknown to the public


A few months ago, and this remains true today, a Google search on 'TLE-400' and HIV gave very few results. Actually only 2: a corporate and financial press release from Mylan (copied and pasted on financial websites) and... Charles-Edouard! Well... Now, there is a little more...

Obviously, this does not help the variety dealers... Let's also remember that it is not yet available in our country while the ENCORE-1 trial was published more than 5 years ago! And meanwhile, services are being closed to save money... Pffff...

Amazing recommendation and prioritization


When we allow, in a so-called recommendation document, a strategy that is obviously better, we are recommending it, without daring to say so.

Here is what Dr. Apollo in Harare, Zimbabwe, has to say about it:
Making the same drug with a little less of the same active ingredient is not an insurmountable industrial challenge! Well... We are not shocked that teenagers from the Third World are given priority... What shocks us is that at the usual rate, the French patient, who pays 600 Euros/month, will receive the cheaper and better tolerated formula... last! Isn't that a bit of an ass? You won't get it before 2-3 years, at best, while Mylan already claims 1 million users! We'll sell out... And who will be eating EFV 600 mg for months and months? It's you...

Morlat, Calmy: same error of judgment


And what does Morlat say about it ? He recommends it:

We have fun with it... First, he explains the 'constraint' of having to take 3 pills. As long as Symfi-Lo has not arrived in France, you're going to have a hard time! Secondly, why restrict yourself to patients who complain? When an overdose is useless, it is useless, even if it is tolerated. Useless is good French and it means what it says. Alexandra Calmy makes the same mistake, by doubling this restriction to patients who complain about a restrictive dosage condition. Well NO... Reducing the dose of VFE is clearly not a dosage restriction! Do you think they do dosing in Zimbabwe??? Prof. Calmy was wrong, and Symfi-Lo proves it, once again

Is 400 mg still too much?


Where is the trial at 200 mg, 300 mg or even 100 mg?

Who remembers that in the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg? Who decided on 600? It was the manufacturer (DuPont Merck)... And no one, no one, has gone back to the drawing board with this univocal decision of the manufacturer. Why 400 and not 500? Because the 200 mg capsule packaging exists, so it's convenient to do a trial.

In fact, we had already reported the words of Pr Kiat RuxRungtham(youtube) who routinely does 300 mg. Well, it's time to ask the question of 200 mg in attack. As far as maintenance is concerned, we are in the midst of a frenzy: the 'threshold' doses are complete nonsense... We'll come back to this...

Dr. Joel Gallant: the moral and ethical fault


Dr. Joel Gallant, a drug promotion frontrunner and principal investigator for Gilead-sponsored trials, published an angry and threatening article condemning the ethical 'misconduct' of those benevolent physicians who bring Mono-DTG into their practice. It was ill-timed, remote-controlled, and in poor taste.

He was also seen ironizing about those patients who would prefer, conditionally, to preserve their psychedelic dreams and remain on Efavirenz. Ironically, to make fun of pharmaco-induced psychic suffering, which still causes thousands of suicides and depressions today, is abject and allows us to measure the immorality of the character.

To promote the latest novelty of Gilead, his sponsor, nothing stops him.

One would have thought that in his time, when he was practicing university medicine, he could have worked to reduce the deleterious effects of over-medication. This was not the case. In the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg. The manufacturer, surrounded by experts(which ones?), had simply neglected this phase II trial. These trials are mandatory, they do it... Are they obliged to take them into account? Well no... You have to do an optimal dose finding trial and you are free to choose the maximum dose. And the deleterious effects? We don't care about that. Dosage is the doctors' problem. DMP 266-005 is to be thrown up.

And guess who was the principal investigator of DMP 266-005? Guess... Dr. Joel Gallant himself! Brrr, that's chilling... I hope that one day these people will be brought to trial...

In the news


- Luc Montagnier and Henri Joyeux launch a petition for precaution in medicine and health

- A study confirms the extent of the damage caused by Depakine. Depakine? That's what Siliciano is considering for his shock-and-kill... Brrr!

Feel free to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

97% of patients overmedicated, 22 million without treatment ... Let's stop this scandal!

Saturday, June 2, 2018

109



This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.




ICCARRE and the New Paradigm

By Charles-Edouard!

Jacques Leibowitch comments on our previous post:
ICCARRE, Jacques Leibowitch Pasteur IAS_2017, rémission

The prevailing dogma is that ICCARRE is impossible. Some claim that we cheated (ANRS-4D = scathing denial). They dare to add that it is only for a few: Quatuor will sink them. Other idolaters say (e.g. Prof. Reynes): 'I hope it won't go any further...' It's laughable: for sure, it will go further... It is the virus that decides... not a mandarin...

Paradigm shift: demonstration at Pasteur


The trailer of the presentation at PASTEUR is on youtube, go there!
Leibowitch starts by presenting the classical picture in 2 steps:

1. Attack-Induction-Reduction:
Attack ARV treatment should in all cases:
- CONTINUOUSLY reduce CV < 50 cp
- Monitor < 50 copies/ml continuously
- Effectively stop any HIV-dependent progression to AIDS diseases
- Reduce the risk of intimate HIV transmission to almost zero
All this, today, in less than 6 months...

ICCARRE and its DISCONTINUTES can then be summoned...: we start the ICCARRian descent(typically 1 year after initiation of treatment)

2. Maintenance Treatment, following effective induction treatment, Cellular Activation and Peri-HIV Inflammation are in Leakage, the Lymphoid Environment is cooled down and HIV is reduced to a very small size in a biotope that is naturally not conducive to replication.

Pharmacokinetics in Failure: Thinking Outside the Box


It has been known for a long time that treatment cannot be stopped without seeing the CV rise. Viscontis could be an exception, the Pasteurians (Dr. Asier Saez-Cirion) have proposed a hypothesis. So they know that pharmacokinetics are insufficient to explain that repeated interruptions of 1 week can be done safely. Demonstrated by FAUCY, the boss of the American NIH. In a way, already announced by B. Autran, an eminent French immunologist.

Pharmacokinetics does not satisfy us, and, what is more, fundamental 'values' are false: Morlat continues to publish values that in Saint Antoine were said to be false (e.g. Nevirapine): Not only the theory is wrong, but also the values!

Parisian virology is wrong: we really need to change our paradigm!

The eternal restart as a new paradigm


ICCARRE, eclipse, ANRS, Quatuor, Leibowitch, Pasteur, vih, cure, rémission
Everyone agrees that there is a gap between infection and seroconversion. Typically 2 to 3 weeks. No one disputes that... Nobody... The post-treatment eclipse has been demonstrated many times.

So it's surprising that the virologists are still predicting an immediate rise in CV if you stop. Well... We are not surprised anymore, actually... Denying the eclipse is as stupid as the moon!

J. Leibowitch's proposal is to say that, post effective treatment and post interruption, HIV unwinds its initial film: it is the eternal non-return, the deficiency, of the primo, repeated as a bonus!

The reader will have noted that the unchanged repetition of the deficiency implies that the eclipse cannot be manipulated (it is a cosmic fact) and that the reservoir has nothing to do with it. The Choke-and-Mute is slightly different, it considers manipulating the eclipse and extending it. Here, Charles-Edouard and Leibowitch differ slightly. No matter... The Eclipse is here: let's take advantage of it!

Post-ARV eclipses as a repeat of two-rate HIV dynamics in vivo:


A- following a recent mucosal infection: primary inoculation
or
B- interruption of synergistic ARVs: chronic infection

It takes time for HIV to complete its reproductive cycle: slow local linear growth, as in difficulty to surface (primary infection) or resurface (post ARVs). Active forms of HIV remain sub-detectable for a while until... the delayed systemic exponential explosion...

Then, Jacques Leibowitch presented the trials and examples: ICCARRE is a proven, robust way. We will see this next time...

Bomsel VIH image live virologie Charles-Edouard Cochin

The French genius


I'm putting back the impressive pictures of the Bomsel team (also present at the seminar... ): a little to underline their technical prowess and also ours to have succeeded in putting it online...

That plus the availability on youtube of the presentation of Leibowitch... On the technical level, we are progressing!

Judiciarization


Patients file suit against Gilead. Below is a commentary from the Los Angeles Times


Here? No one told you about that... In any case, the enormous profits made are undoubtedly a breeding ground for dubious practices. We can find traces of what Gilead spends money on: ParisSansSida, ActUp-Paris, etc. It's up to you to make up your own mind...

Do not hesitate to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

Friday, June 1, 2018

108



This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.




Choke and Mute: Seminar at Pasteur

By Charles-Edouard!

ICCARRE invited to the Pasteur Institute


ICCARRE eclipse ANRS Quatuor Olivier Schwartz Pasteur séminaire
Each presentation of Jacques Leibowitch or 4/7, in conference, arouses enthusiasm. Hugs, awards, laughter, congratulations, hearty applause, standing ovations: it never fails!

During IAS-2017, we had skilfully countered the deprogramming of ICCARE: Dr Turkova, not being shy, had slipped ICCARRE into her presentation. An invisible hand, not innocent, will have cut his entire presentation from the video session, in the editing. Well... It plays very small...

Parisian virology, mainly rotten, is nevertheless diverse, and the foundations of expensive and toxic 'medicine' has its detractors. Delelis has once again demonstrated that the classical dogma of the necessary integration into the DNA is incomplete and therefore false. Our biologists are saving the honor, even if their progress is hindered.

At Pasteur, we remember that the samples that allowed the famous discovery of the Virus (and 2 Nobel prizes) did not arrive at the Laboratory by themselves. The Pasteurian memory crosses that of ICCARRE at regular intervals. ICCARRE, dedicated, is also of interest to biologists: Dr. Olivier Schwartz, Scientific Director of the Pasteur Institute, thought it appropriate to invite J. Leibowitch to a dedicated seminar, on May 17, 2018. All the top brass of HIV biology were there: Pasteur, ENS, Inserm, Institut Cochin ... Françoise Barré-Sinoussi, always Pasteur at heart, would have been there if she had not been prevented from attending, which O. Schwartz was kind enough to ask us to excuse. No problem! Everyone, including you, will be able to view the presentations.

ICCARRE and the Paradigm shift


ICCARRE eclipse ANRS Quatuor Olivier Schwartz Pasteur séminaire
Pharmacokinetics could serve as a reasonable explanation for 5/7, but not at all for 1/7: we need to change the paradigm and revisit the foundations of HIV biology. With the exception of Dr. Hutter (Berlin), no doctor has ever cured a single (HIV/AIDS) patient. This should make us question ourselves a bit!

When thinking about ICCARRE, one should always keep in mind the characteristic curve of the Eclipse, otherwise one is on the wrong track. In 3 phases: down for a few days, then a sub-detectable rise, crossing the threshold of detectability to end in a spectacular ejaculation. Well... For those who have understood, it is obvious.

From ICCARRE to CHOKE-and-MUTE


Institut Pasteur séminaire paradigme
Pierre Sonigo has explained many times to J. Leibowitch this dynamic chain reaction. For Sonigo or Kupieck, it is the basis of a(systemic?) biology, so fundamental and general, that they do not bother to popularize the HIV-specific version. J. Leibowitch takes it up in his book 'Pour en finir avec le Sida'. It deserves some light, which is normal for an eclipse.

The The prevailing dogma is a misconceptionand the best way to fight a misconception is to come up with a visibly better one!

It is here that yours truly, inspired by his masters, had the idea to create a didactic tool: it is the Eclipse Equation, which Leibowitch commented, rightly so:


Well done! Thus, we are going to make the New Equation of the Eclipse which exposes a way to remission, alternative to the dominant theory. Dominant... and failing, need we remind you?

Here is how, for the sake of clarity, appears on a popularizing blog an innovative concept, baptized by us theChoke-and-Mute. Indeed, ICCARRE, beyond the anecdotal relief (the 4/7, small arm), is a way to Remission! It is even an obligatory step: how could a patient who fails the 1/7 succeed the 0/365? Pass ICCARRE 1/7 and then we'll see!

Choke and Mute: Baptism at the Pasteur Institute


Choke-and-Mute eclipse ANRS Quatuor Charles-Edouard Pasteur séminaire
The paradigm shift made necessary by 1/7 goes hand in hand with a new theory of remission. The one cannot go without the other... Hence the idea of exhibiting them together in Pasteur. But then, in Pasteur, the holy of holies of world biology, you can't miss it! And it's May 17 or never, it's in a few weeks, and if the scientific direction of Pasteur is willing... Oh dear! What a challenge!

The text has been worked on, amended and revised. It remains to integrate it to Leibo's PowerPoint. Argh!!! We are caught by time! Catastrophe, it's now or never! It's for a seminar at Pasteur, and Leibo is polishing his slides, the paradigm shift. Oh! No time for Choke-and-Mute...

Disaster in the making! And we are saved: O. Schwartz accepts the principle of 2 presentations: the paradigm shift, by Leibo, and the Choke-and-Mute by... Charles-Edouard!... And that, from one day to the next!

Choke and Mute: Applause at Pasteur


Well... Despite some technical difficulties (ah... computers...) and with the help of the Pasteurians, we did great! It was really great!

We have to admit that ICCARRE, the 4/7, the Morlat recommendation, ANRS-4D, Quatuor, paradigm shift, the Eclipse, its equation, the Choke-and-Mute, and a plea for ICCARRian research, all in 1 hour, it's dense!

In a small seminar, with a learned and specialized audience, it's a good thing! Thanks to all! The hearty applause was our reward! Oh, it's clear! We have changed dimension!

The videos will be online soon


The presentations will soon be available online, in replay, once the English versions are finalized. To have them, in trial version, please leave an email address in the comments (your address will not be published).

In the news


Let's be modest: the news that counts is us! There was also:

- Immunology/Cancer: CAR-T cell breakthrough confirmed

- Finally... Finally! The first commercial 'lighter' has arrived on the market. It is the TLE-400 that we were talking about here. You will notice that nobody else is talking about it... Hi, Hi, Hi.... And Mylan introduces CimDuo ... This will do our finances a world of good, including PreP...

The French genius


Bomsel VIH image live virologie Charles-Edouard Cochin
Impressive images:
Live imaging of HIV-1 transfer across the virological synapse the T4 cell by Fernando Real et al. (and Morgane Bomsel, incidentally present at the seminar... )

List of videos (to be viewed separately)

- Video #1
- Video #2
- Video #3
- Video #4
- Video #5
- Video #6
- Video #7
- Video #8




Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!